apoquel,
oclacitinib,
OCLACITINIB,
1208319-26-9,
PF-03394197,
JAKI,
PF-03394197(Oclacitinib),
UNII-99GS5XTB51,
99GS5XTB51,
PF03394197,
N-Methyl-1-(trans-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide,
Apoquel,
N-Methyl-1-((1r,4r)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide,
Oclacitinib [USAN:INN],
N-methyl-1-(4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide,
N-methyl-1-[4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]methanesulfonamide,
Oclacitinib (USAN),
Apoquel (veterinary use),
SCHEMBL261673,
SCHEMBL261679,
Oclacitinib,PF-03394197,
GTPL9696,
CHEMBL2103874,
SCHEMBL19229712,
SCHEMBL19273287,
BDBM185700,
Oclacitinib (PF-03394197),
AOB87738,
BCP07898,
EX-A1602,
KS-00000M8Y,
MFCD25976611,
PF-03394197, JAKi,
ZINC84757327,
AKOS026750309,
ZINC261515681,
CS-3277,
US9161939, 1a,
NCGC00390707-03,
AK499444,
AS-17051,
BC600714,
HY-13577,
QC-11804,
AX8279258,
B5960,
J3.500.188C,
PF 03394197,
A13082,
D10141,
Cyclohexanemethanesulfonamide, N-methyl-4-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4- ylamino)-, trans-,
N-Methyl(trans-4-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclohexyl) methanesulfonamide,
N-methyl-1-[(1r,4r)-4-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]cyclohexyl]methanesulfonamide,
Oclacitinib [USAN],
trans-;N-methyl-1-((1r,4r)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide,